"antipeptide (EGVYVHPV), angiotensin II, human (DRVYIHPF), and isotopically (13C) labeled heptapeptide (AAAAHAA-NH2 [where “A” indicates a carbon thirteen (13C) isotope on the alanine carbonyl group]) were purchased from CPC Scientific Incorporated (Sunnyvale, CA)"
Abstract
It is shown that y-type ions, after losing C-terminal H2O or NH3, can lose an internal backbone carbonyl (CO) from different peptide positions and yield structurally different product fragment ions upon collision-induced dissociation (CID). Such CO losses from internal peptide backbones of y-fragment ions are not unique to a single peptide and were observed in four of five model peptides studied herein. Experimental details on examples of CO losses from y-type fragment ions for an isotopically labeled AAAAHAA-NH2 heptapeptide and des-acetylated-α-melanocyte-stimulating hormone (dα-MSH) (SYSMEHFRWGKPV-NH2) are reported. Results from isotope labeling, tandem mass spectrometry (MSn), and ion mobility-mass spectrometry (IM-MS) confirm that CO losses from different amino acids of m/z-isolated y-type ions yield structurally different ions. It is shown that losses of internal backbone carbonyls (as CID products of m/z-isolated y-type ions) are among intermediate steps towards formation of rearranged or permutated product fragment ions. Possible mechanisms for generation of the observed sequence-scrambled a-“like” ions, as intermediates in sequence-scrambling pathways of y-type ions, are proposed and discussed.
SOCIAL MEDIA
Connect with us and stay updated by following our social media channels.
Latest Briefings from our Knowledge Center
Press Releases, Industry News, Articles, and Technical Content
CPC Scientific is thrilled to return to CPHI Frankfurt 2025! Explore a tour of our booth as we recap key moments from Day 1 of CPHI Frankfurt, where we're highlighting our position as a global pioneer in peptide and oligonucleotide CDMO services...
In today’s biotech landscape, quality is essential. For therapeutics based on peptides or oligonucleotides, many of which treat complex or life-threatening conditions, GMP compliance is a foundational element of regulatory approval and patient trust.
At CPC Scientific, we know that peptide programs rarely move in a straight line. That’s why our FTE services are designed to provide dedicated scientific support, supplementing your team with our CRDMO manufacturing expertise and facilities...
Selecting the right partner can directly impact both speed-to-market and long-term commercial success, particularly for peptide and oligo programs. A CDMO addresses this by providing support across the drug development lifecycle.
At CPHI Frankfurt 2025, CPC Scientific will spotlight its position as a global leader in peptide and oligonucleotide CRDMO solutions. As the company’s largest event of the year, the showcase will emphasize innovation, regulatory excellence, and a proven track record of supporting partners worldwide. Visitors can connect with CPC Scientific’s leadership and scientific team at Booth 12.0F29 to explore new opportunities and collaborations.
Peptide–oligo conjugates are innovative hybrid molecules uniting the targeting precision of peptides with the gene-modulating power of oligos. However, harnessing their potential requires overcoming significant technical barriers...
CPC Scientific is back at Boulder Peptide Symposium 2025 as a Gold Sponsor! Discover key moments from the symposium and see how our team is pioneering innovations in large-scale synthesis as a leading peptide manufacturer...
We recently caught up with Chief Solutions Officer Baosheng Liu, PhD to discuss how CPC Scientific is shaping the future of peptide and oligo manufacturing, and how the CDMO industry is evolving in the next decade...
A hot trend in the diagnostic field is the development of noninvasive peptide biosensors for real-time disease detection. The use of engineered peptide substrates to detect protease activity in human breath is a novel diagnostic strategy...